The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

Nearly 4.4 million adult New Yorkers, or 30%, have obesity, but access to weight-loss medications varies based on a variety ...

Lawsuit is part of a nationwide strategy by Novo Nordisk to protect its trademark and profits from its blockbuster GLP-1 ...

Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) ...

Wegovy a professionally prescribed drug for weight executives has acquired consideration for its viability in assisting people with accomplishing critical weight reduction On the off chance that youre ...

Medicare may cover Wegovy for adults with cardiovascular disease and either obesity or overweight. Learn more about Medicare ...

Doctors are sending out a warning after children as young as 10 years old are using drugs like Ozempic and Wegovy.